1. PET markers of tau and neuroinflammation are co-localized in progressive supranuclear palsy
- Author
-
Franklin I. Aigbirhio, Maura Malpetti, Young T. Hong, Patricia Vázquez Rodríguez, Luca Passamonti, W Richard Bevan-Jones, Tim D. Fryer, John T. O'Brien, P. Simon Jones, Timothy Rittman, and James B. Rowe
- Subjects
0303 health sciences ,Tau pathology ,business.industry ,Binding potential ,Ligand (biochemistry) ,medicine.disease ,Progressive supranuclear palsy ,03 medical and health sciences ,0302 clinical medicine ,In vivo ,mental disorders ,Medicine ,Clinical severity ,business ,Neuroscience ,030217 neurology & neurosurgery ,Neuroinflammation ,030304 developmental biology - Abstract
BackgroundProgressive Supranuclear Palsy (PSP) is associated with tau-protein aggregation and neuroinflammation, but it remains unclear whether these pathogenic processes are relatedin vivo.ObjectivesWe examined the relationship between tau pathology and microglial activation using [18F]AV-1451 (indexing tau burden) and [11C]PK11195 (microglial activation) PET in n=17 patients with PSP-Richardson’s syndrome.MethodsNon-displaceable binding potential (BPND) for each ligand was quantified in 83 regions of interest (ROIs). [18F]AV-1451 and [11C]PK11195 BPNDvalues were correlated across all ROIs. The anatomical patterns of [18F]AV-1451 and [11C]PK11195 binding co-localization was determined across sets of regions derived from principal component analyses (PCAs). Finally, PCA-derived brain patterns of tau pathology and neuroinflammation were linked to clinical severity.Results[18F]AV-1451 and [11C]PK11195 binding were positively related across all ROIs (r=0.577, p18F]AV-1451 and [11C]PK11195 components were found in sub-cortical (r=0.769, pConclusionsWe show that tau pathology and neuroinflammation co-localize in PSP, and that individual differences in subcortical tau pathology and neuroinflammation are linked to clinical severity. Although longitudinal studies are needed to determine how these molecular pathologies are causally linked, we suggest that the combination of tau- and immune-oriented strategies may be useful for effective disease-modifying treatments in PSP.
- Published
- 2019
- Full Text
- View/download PDF